Novamind reports revenues of CAD$1.86 million for Q1 fiscal 2022, a 113% year-over-year increase. The company has total working capital of CAD$6.8 million
Novamind reports revenues of CAD$1.86 million for Q1 fiscal 2022, a 113% year-over-year increase. The company has total working capital of CAD$6.8 million
Novamind announces unified branding of all subsidiaries and brands, and includes a new corporate logo.
Seelos Therapeutics announces $20 million in new funding via convertible note, with an option for an additional $30 million.
The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.
MindMed announces its Q3 2021 results. Continued progress on R&D and pipeline development. Cash and equivalents of $178.6 million.
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.
Numinus' Montreal and Vancouver clinics will be host for an extension of the MAPS Phase III clinical trial on MDMA-assisted therapy for PTSD.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now